Skip to main content
OpenTrials
Completed

NCT Number: NCT04631315

Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.

This controlled, randomized, double blind, multicenter study will be carried out to demonstrate that the topical ophthalmic nanoemulsion of difluprednate 0.05% (Tolf®, Poen Laboratories), has a high anti-inflammatory efficacy, which would allow it to be administered after cataract surgery 1 drop, twice a day , starting the day before surgery and continuing for 14 days and 1 drop, once a day for the following 2 weeks, achieving an adequate anti-inflammatory activity, with the benefit of reducing the toxicity on the ocular surface, improving the dosage and adherence to treatment.

The follow-up time will be 28 days and the outcome measures will be evaluated in a baseline (time 0), on day 1, on day 4 and on day 28 after surgery. The active control will be prednisolone acetate 1% + phenylephrine hydrochloride 0.12% topical ophthalmic suspension (Prednefrin® Forte, Allergan Argentina) given 1 drop, 4 times a days and 1 drop, twice a day for the next 2 weeks. Corneal thickness, central macula thickness, endothelial cell count, intraocular pressure, visual acuity, anterior chamber clearance and lacrimal film recovery will be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Eye Diseases Lens Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Laboratorios Poen

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., C1407BDR, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes between 45 and 65 years old (women who are not fertile) who undergo cataract surgery N2 and N3, defined according to BCN10, Decimal classification of cataracts.
  • That the surgical technique is ultrasonic phacoemulsification.
  • Patients who have an initial corneal thickness between 500 and 570 µm inclusive.
  • Patients with initial intraocular pressure between 12 and 18 mm Hg inclusive.
  • Patients with an endothelial cell count greater than 1000 cells / mm2

Exclusion criteria

  • Patients who use eye medication, except eye lubricant.
  • Patients who before surgery have not been able to dilate their pupil more than 5 mm
  • Patients who have been treated with corticosteroids or systemic anti-inflammatory drugs for 2 weeks prior to enrollment
  • Patients who have received periocular corticosteroid injections in the study eye within the previous 4 weeks or used depot corticosteroids within 2 months prior to enrollment
  • Patients who have received a topical ocular corticosteroid or non-steroidal anti-inflammatory drug (NSAID) within 24 hours prior to enrollment
  • History of glaucoma or ocular hypertension in the study eye, history or presence of endogenous uveitis, or corneal abrasion or ulceration
  • Patients with a diagnosis or suspicion of keratoconjunctival disease caused by viruses, bacteria, or fungi
  • Patients which presents an allergy to the drug to be tested or to any similar drug such as other corticosteroids
  • History of increased intraocular pressure due to the use of corticosteroids
  • Patients with pathological macular features
  • Diabetics
  • Breastfeeding women
  • Patients with rheumatoid arthritis.
  • Patients treated with Amiodarone

Treatment and study plan

Difluprednate ophthalmic emulsion 0.05%

Drug

1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.

Other names: Tolf®

Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution

Drug

1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.

Primary outcomes

  1. Change from baseline corneal thickness between treatments

    Time frame: Baseline to visit 3 (96 hours from surgery)

    Demonstrate that 0.05% difluprednate ophthalmic nanoemulsion administered 1 drop, 2 times a day, beginning the day before cataract surgery and continuing for the first 14 postoperative days and then 1 drop, once a day for the next 14 days, it does not present an anti-inflammatory efficacy lower than treatment with prednisolone acetate 1% + phenylephrine hydrochloride 0.12% ophthalmic suspension administered 1 drop, 4 times a day starting the day before surgery and continuing during the first 14 post-surgical days and 1 drop , 2 times a day for the next 14 days, for the treatment of postsurgical inflammation, in patients operated on for N2 and N3 cataracts.

    Difluprednate 0.05% ophthalmic nanoemulsion will not be clinically inferior than Prednisolone acetate 1% + 0.12% phenylephrine hydrochloride ophthalmic suspension, if the difference in corneal thickness obtained with OCT between the baseline day and the post-surgical day it does not differ beyond 17 µm between treatments.

Secondary outcomes

  1. Retinal Thickness

    Time frame: Day before surgery (-1); Day 1 after surgery (1); Day 4 after surgery (4); 28 days post surgery (28)

    Retinal Thickness measured by Optical Coherence Tomography (mm)

  2. Corneal endothelial cell count

    Time frame: Day before surgery (-1); Day after surgery (1); Day 4 after surgery (4); 28 days post surgery (28).

    Corneal endothelial cell count measured by specular microscope (cells/mm2)

  3. Visual acuity

    Time frame: Day before surgery (-1); Day after surgery (1); Day 4 after surgery (4); 28 days post surgery (28).

    Visual acuity measured by visual acuity standardized chart (20/20)

  4. Flare and cell on anterior chamber

    Time frame: Day before surgery (-1); Day after surgery (1); Day 4 after surgery (4); 28 days post surgery (28).

    Presence of flare and cells on anterior chamber using slit lamp (biomicroscopy)

  5. Intraocular pressure

    Time frame: Day before surgery (-1); Day after surgery (1); Day 4 after surgery (4); 28 days post surgery (28).

    Intraocular pressure measured by Goldmann tonometer (mmHg)

  6. Equal safety profile of both treatments

    Time frame: Day before surgery (-1); Day 1 after surgery (1); Day 4 after surgery (4); 28 days post surgery (28)

    Report of adverse events of both treatments under study

  7. Corneal Thickness by pachymetry

    Time frame: Day before surgery (-1); Day after surgery (1); Day 4 after surgery (4); 28 days post surgery (28).

    Corneal Thickness (mm)

Sponsors and collaborators

Lead sponsor

Laboratorios Poen

Industry

Registry information

Official study title

Efficacy and Safety of Difluprednate Ophthalmic Emulsion vs. a Fixed-Combination of Prednisolone Acetate - Phenylephrine Ophthalmic Suspension on Post-operative Inflammation Following Cataract Surgery.

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Nov 17, 2020
Registry last updated
May 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.